{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:44:48Z","timestamp":1795016688803,"version":"4.10.1"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073213"],"award-info":[{"award-number":["82073213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2021\\u201346-2503"],"award-info":[{"award-number":["Z-2021\\u201346-2503"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["MSXM2025006"],"award-info":[{"award-number":["MSXM2025006"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017534","name":"333 Project of Jiangsu Province","doi-asserted-by":"publisher","award":["2022\\u20133-25\\u2013162"],"award-info":[{"award-number":["2022\\u20133-25\\u2013162"]}],"id":[{"id":"10.13039\/501100017534","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251791"],"award-info":[{"award-number":["BK20251791"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018592","name":"\u201c333 Project\u201d of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bcp.2026.117716","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:46:25Z","timestamp":1768776385000},"page":"117716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies"],"prefix":"10.1016","volume":"246","author":[{"given":"Yihua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-6909","authenticated-orcid":false,"given":"Zeyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.bcp.2026.117716_b0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117716_b0015","doi-asserted-by":"crossref","unstructured":"F.M. Walter, G. Rubin, C. Bankhead, H.C. Morris, N. Hall, K. Mills, C. Dobson, R.C. Rintoul, W. Hamilton, J. Emery, Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study, Br J Cancer 112 Suppl 1(Suppl 1) (2015) S6\u201313.","DOI":"10.1038\/bjc.2015.30"},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.bcp.2026.117716_b0025","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdn635","article-title":"MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients","volume":"20","author":"Cappuzzo","year":"2009","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117716_b0035","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.bcp.2026.117716_b0050","first-page":"2752","article-title":"Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors","volume":"55","author":"Owens","year":"1995","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.117716_b0055","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.29522","article-title":"Targeting FAK scaffold functions inhibits human renal cell carcinoma growth","volume":"137","author":"B\u00e9raud","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.bcp.2026.117716_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144250","article-title":"Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0065","first-page":"215","article-title":"Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses","volume":"9","author":"Lark","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/13543784.2020.1740680","article-title":"FAK targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials","volume":"29","author":"Mohanty","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/bies.950190208","article-title":"Signaling through focal adhesion kinase","volume":"19","author":"Hanks","year":"1997","journal-title":"Bioessays"},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0085","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1083\/jcb.123.4.993","article-title":"Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions","volume":"123","author":"Hildebrand","year":"1993","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117716_b0090","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2007.05.041","article-title":"Structural basis for the autoinhibition of focal adhesion kinase","volume":"129","author":"Lietha","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1074\/jbc.M509188200","article-title":"Crystal structure of the FERM domain of focal adhesion kinase","volume":"281","author":"Ceccarelli","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0100","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1083\/jcb.130.5.1181","article-title":"Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains","volume":"130","author":"Schaller","year":"1995","journal-title":"J. Cell Biol."},{"issue":"13","key":"10.1016\/j.bcp.2026.117716_b0105","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/MCB.02186-05","article-title":"Direct interaction of focal adhesion kinase (FAK) with met is required for FAK to promote hepatocyte growth factor-induced cell invasion","volume":"26","author":"Chen","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12860-019-0193-4","article-title":"High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site","volume":"20","author":"Marlowe","year":"2019","journal-title":"BMC Mol. Cell Biol."},{"issue":"6508","key":"10.1016\/j.bcp.2026.117716_b0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/372786a0","article-title":"Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase","volume":"372","author":"Schlaepfer","year":"1994","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.bcp.2026.117716_b0120","doi-asserted-by":"crossref","first-page":"17788","DOI":"10.1074\/jbc.M100984200","article-title":"Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397","volume":"276","author":"Salazar","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0125","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1073\/pnas.89.11.5192","article-title":"pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions","volume":"89","author":"Schaller","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0130","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0969-2126(02)00907-3","article-title":"Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography","volume":"10","author":"Nowakowski","year":"2002","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.bcp.2026.117716_b0135","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","article-title":"Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271","volume":"68","author":"Roberts","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117716_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejmech.2012.06.035","article-title":"Discovery and characterization of novel allosteric FAK inhibitors","volume":"61","author":"Iwatani","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0145","doi-asserted-by":"crossref","first-page":"e3800","DOI":"10.1371\/journal.pone.0003800","article-title":"Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation","volume":"3","author":"Lietha","year":"2008","journal-title":"PLoS One"},{"issue":"43","key":"10.1016\/j.bcp.2026.117716_b0150","doi-asserted-by":"crossref","first-page":"23327","DOI":"10.1002\/anie.202109237","article-title":"Discovery and Characterisation of Highly Cooperative FAK degrading PROTACs","volume":"60","author":"Law","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0155","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1119356","article-title":"FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy","volume":"5","author":"Serrels","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1083\/jcb.201307067","article-title":"Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function","volume":"204","author":"Jean","year":"2014","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0165","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.bcp.2026.117716_b0170","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104743","article-title":"Structural basis of Focal Adhesion Kinase activation on lipid membranes","volume":"39","author":"Acebr\u00f3n","year":"2020","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0175","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nrm2996","article-title":"The FERM domain: organizing the structure and function of FAK","volume":"11","author":"Frame","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1083\/jcb.143.2.547","article-title":"Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis","volume":"143","author":"Ili\u0107","year":"1998","journal-title":"J. Cell Biol."},{"issue":"26","key":"10.1016\/j.bcp.2026.117716_b0185","doi-asserted-by":"crossref","first-page":"25008","DOI":"10.1074\/jbc.M414172200","article-title":"Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53","volume":"280","author":"Golubovskaya","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0190","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/BJ20071657","article-title":"The 7-amino-acid site in the proline-rich region of the N-terminal domain of p53 is involved in the interaction with FAK and is critical for p53 functioning","volume":"411","author":"Golubovskaya","year":"2008","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2007.11.031","article-title":"Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation","volume":"29","author":"Lim","year":"2008","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2010.10.008","article-title":"p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines","volume":"300","author":"Anaganti","year":"2011","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/gutjnl-2018-317424","article-title":"Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion","volume":"69","author":"Jiang","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2026.117716_b0215","doi-asserted-by":"crossref","unstructured":"Newport, A.R. Pedrosa, D. Lees, M. Dukinfield, E. Carter, J. Gomez-Escudero, P. Casado, V. Rajeeve, L.E. Reynolds, R.C. P, S.W. Duffy, B. De Lux\u00e1n Delgado, K. Hodivala-Dilke, Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth, J Pathol 256(2) (2022) 235\u2013247.","DOI":"10.1002\/path.5833"},{"issue":"16","key":"10.1016\/j.bcp.2026.117716_b0220","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.febslet.2008.06.004","article-title":"FAK nuclear export signal sequences","volume":"582","author":"Ossovskaya","year":"2008","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0225","doi-asserted-by":"crossref","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2020.0273","article-title":"Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells","volume":"18","author":"Osipov","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0235","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41418-020-00651-5","article-title":"KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway","volume":"28","author":"Du","year":"2021","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0240","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.7150\/jca.14713","article-title":"AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells","volume":"7","author":"Abdelhamed","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2026.117716_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 Expression by NF-\u03baB in Cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010094","article-title":"Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-negative Breast Cancer","volume":"12","author":"Pan","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0260","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","article-title":"FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer","volume":"73","author":"Canel","year":"2023","journal-title":"Gut"},{"issue":"15","key":"10.1016\/j.bcp.2026.117716_b0270","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/onc.2015.256","article-title":"Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis","volume":"35","author":"Zhang","year":"2016","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2026.117716_b0275","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment is a driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.117716_b0280","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1158\/0008-5472.CAN-17-1307","article-title":"Downregulation of Membrane trafficking Proteins and Lactate Conditioning Determine loss of Dendritic Cell Function in Lung Cancer","volume":"78","author":"Caronni","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0285","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-12-0388","article-title":"RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas","volume":"3","author":"Konstantinidou","year":"2013","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0290","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/s44321-024-00138-7","article-title":"ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer","volume":"16","author":"Pozzato","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"23","key":"10.1016\/j.bcp.2026.117716_b0295","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1158\/1078-0432.CCR-15-2603","article-title":"Focal Adhesion Kinase Regulates the DNA damage Response and its Inhibition Radiosensitizes Mutant KRAS Lung Cancer","volume":"22","author":"Tang","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6543","key":"10.1016\/j.bcp.2026.117716_b0300","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/376737a0","article-title":"Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions","volume":"376","author":"Lev","year":"1995","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bcp.2026.117716_b0305","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.1073\/pnas.1834348100","article-title":"Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration","volume":"100","author":"Okigaki","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0310","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202307150","article-title":"Formation and function of multiciliated cells","volume":"223","author":"Lyu","year":"2024","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0315","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.bjc.6603827","article-title":"The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence","volume":"97","author":"Sun","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12964-024-01639-1","article-title":"Integrin \u03b1V\u03b21-activated PYK2 promotes the progression of non-small-cell lung cancer via the STAT3-VGF axis","volume":"22","author":"Wu","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"9","key":"10.1016\/j.bcp.2026.117716_b0325","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"37","key":"10.1016\/j.bcp.2026.117716_b0330","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0335","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx157","article-title":"Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer","volume":"110","author":"Zhou","year":"2018","journal-title":"J. Natl Cancer Inst."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0340","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1093\/nar\/gkv210","article-title":"Identification of recurrent regulated alternative splicing events across human solid tumors","volume":"43","author":"Danan-Gotthold","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"7573","key":"10.1016\/j.bcp.2026.117716_b0345","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nature15258","article-title":"Alternative transcription initiation leads to expression of a novel ALK isoform in cancer","volume":"526","author":"Wiesner","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0350","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/MCB.00709-10","article-title":"Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer","volume":"31","author":"Misquitta-Ali","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"45","key":"10.1016\/j.bcp.2026.117716_b0355","doi-asserted-by":"crossref","first-page":"28720","DOI":"10.1074\/jbc.272.45.28720","article-title":"Alternatively spliced focal adhesion kinase in rat brain with increased autophosphorylation activity","volume":"272","author":"Burgaya","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.117716_b0360","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1471-2164-7-198","article-title":"Organization and post-transcriptional processing of focal adhesion kinase gene","volume":"7","author":"Corsi","year":"2006","journal-title":"BMC Genomics"},{"issue":"22","key":"10.1016\/j.bcp.2026.117716_b0365","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1128\/MCB.22.22.7731-7743.2002","article-title":"Alternative splicing controls the mechanisms of FAK autophosphorylation","volume":"22","author":"Toutant","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0370","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/15230860260196290","article-title":"Antiapoptotic action of focal adhesion kinase (FAK) against ionizing radiation","volume":"4","author":"Kasahara","year":"2002","journal-title":"Antioxid. Redox Signal."},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0375","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1172\/JCI61350","article-title":"\u03b21Integrin\/FAK\/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy","volume":"122","author":"Eke","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0380","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju419","article-title":"Simultaneous \u03b21 integrin-EGFR targeting and radiosensitization of human head and neck cancer","volume":"107","author":"Eke","year":"2015","journal-title":"J. Natl Cancer Inst."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027806","article-title":"FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells","volume":"6","author":"Graham","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0390","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-23-0964","article-title":"FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner","volume":"30","author":"Pifer","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"37","key":"10.1016\/j.bcp.2026.117716_b0395","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb2630","article-title":"Extracellular matrix stiffness determines DNA repair efficiency and cellular sensitivity to genotoxic agents","volume":"6","author":"Deng","year":"2020","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0400","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/2159-8290.CD-22-0192","article-title":"Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to allow for Immune Priming and Response to Checkpoint Blockade","volume":"12","author":"Lander","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0405","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3892\/ijo.2017.4141","article-title":"Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner","volume":"51","author":"Jung","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117716_b0410","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/09553000310001610231","article-title":"Ionizing radiation modules of the expression and tyrosine phosphorylation of the focal adhesion\u2010associated proteins focal adhesion kinase (FAK) and its substrates p130cas and paxillin in A549 human lung carcinoma cells in vitro","volume":"79","author":"Beinke","year":"2003","journal-title":"Int. J. Radiat Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0415","doi-asserted-by":"crossref","first-page":"635","DOI":"10.7150\/ijbs.52319","article-title":"ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal transition","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0420","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41420-025-02757-6","article-title":"FHL2 enhances ITGB1-mediated ECM remodeling and cellular stiffness to promote radioresistance in non-small cell lung cancer","volume":"11","author":"Pu","year":"2025","journal-title":"Cell Death Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0425","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-16-2300","article-title":"SFK\/FAK Signaling Attenuates Osimertinib Efficacy in both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer","volume":"77","author":"Ichihara","year":"2017","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.bcp.2026.117716_b0430","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1074\/jbc.M606695200","article-title":"Cellular characterization of a novel focal adhesion kinase inhibitor","volume":"282","author":"Slack-Davis","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.bcp.2026.117716_b0435","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in patients with Advanced Treatment Refractory Pancreatic Cancer: a phase I Dose Escalation and expansion Study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0440","first-page":"1680","article-title":"Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src","volume":"14","author":"Schaller","year":"1994","journal-title":"Mol. Cell Biol."},{"issue":"42","key":"10.1016\/j.bcp.2026.117716_b0445","doi-asserted-by":"crossref","first-page":"26329","DOI":"10.1074\/jbc.271.42.26329","article-title":"Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase","volume":"271","author":"Chen","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0450","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1128\/MCB.16.10.5623","article-title":"Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases","volume":"16","author":"Schlaepfer","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.117716_b0455","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bcp.2026.117716_b0460","doi-asserted-by":"crossref","unstructured":"S. Banerjee, M.G. Krebs, A. Greystoke, A.I. Garces, V.S. Perez, A. Terbuch, R. Shinde, R. Caldwell, R. Grochot, M. Rouhifard, R. Ruddle, B. Gurel, K. Swales, N. Tunariu, T. Prout, M. Parmar, S. Symeonides, J. Rekowski, C. Yap, A. Sharp, A. Paschalis, J. Lopez, A. Minchom, J.S. de Bono, U. Banerji, Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial, Nat. Med. 31(9)(2025): 3074-3080.","DOI":"10.1038\/s41591-025-03763-y"},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0465","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/neuonc\/noy078","article-title":"A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098","volume":"20","author":"Brown","year":"2018","journal-title":"Neuro Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0470","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0475","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","article-title":"A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours","volume":"120","author":"Mak","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.bcp.2026.117716_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127459","article-title":"Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine\/pyrimidine derivatives as potential FAK inhibitors","volume":"30","author":"Xie","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.bcp.2026.117716_b0485","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","article-title":"Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors","volume":"30","author":"Infante","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117716_b0490","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bcp.2013.07.024","article-title":"The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation","volume":"86","author":"Wiemer","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41389-018-0032-z","article-title":"Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype","volume":"7","author":"Hirt","year":"2018","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0500","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-019-00620-0","article-title":"Phase I Study of the Focal Adhesion Kinase Inhibitor BI853520 in Japanese and Taiwanese patients with Advanced or Metastatic Solid Tumors","volume":"14","author":"Doi","year":"2019","journal-title":"Target. Oncol."},{"issue":"17","key":"10.1016\/j.bcp.2026.117716_b0505","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2014-03-563981","article-title":"Pyk2 promotes tumor progression in multiple myeloma","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.bcp.2026.117716_b0510","doi-asserted-by":"crossref","first-page":"32442","DOI":"10.1021\/acsomega.2c03951","article-title":"Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase","volume":"7","author":"Shi","year":"2022","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.bcp.2026.117716_b0515","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0520","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","article-title":"A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Jones","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0525","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","article-title":"A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors","volume":"77","author":"Shimizu","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0530","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo after First-Line Chemotherapy in patients with Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-blind Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0535","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11523-018-00617-1","article-title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in patients with Advanced or Metastatic Nonhematologic Malignancies","volume":"14","author":"de Jonge","year":"2019","journal-title":"Target Oncol."},{"issue":"31","key":"10.1016\/j.bcp.2026.117716_b0540","doi-asserted-by":"crossref","first-page":"51733","DOI":"10.18632\/oncotarget.18517","article-title":"Inhibition of FAK kinase activity preferentially targets cancer stem cells","volume":"8","author":"Kolev","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bcp.2026.117716_b0545","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13238-020-00732-8","article-title":"FAK targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice","volume":"11","author":"Gao","year":"2020","journal-title":"Protein Cell"},{"issue":"15","key":"10.1016\/j.bcp.2026.117716_b0550","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0555","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/14756366.2022.2100886","article-title":"Design, synthesis, and biological evaluation of potent FAK degrading PROTACs","volume":"37","author":"Qin","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bcp.2026.117716_b0560","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.851065","article-title":"FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways","volume":"12","author":"Huo","year":"2022","journal-title":"Front. Oncol."},{"issue":"49","key":"10.1016\/j.bcp.2026.117716_b0565","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.117716_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116246","article-title":"Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors FAK Based Dual Target Inhibitors and PROTAC Degraders","volume":"224","author":"Yang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117716_b0570","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112868","article-title":"FAK targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer","volume":"408","author":"Liu","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.117716_b0580","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","article-title":"A novel FAK degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects","volume":"45","author":"Xu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0590","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0595","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2533\/chimia.2022.341","article-title":"Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design","volume":"76","author":"Cecchini","year":"2022","journal-title":"Chimia (Aarau)"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0600","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-022-01707-5","article-title":"PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy","volume":"22","author":"Kelm","year":"2023","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0605","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2026.117716_b0610","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1021\/acs.jmedchem.2c01817","article-title":"Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins","volume":"66","author":"Ng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bcp.2026.117716_b0615","doi-asserted-by":"crossref","first-page":"11615","DOI":"10.1021\/acs.jmedchem.0c00793","article-title":"Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): the next step toward Pharmaceutical applications","volume":"63","author":"Goracci","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.117716_b0620","article-title":"A one-pot photocatalytic triazole-based linkerology for PROTACs","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep. Phys. Sci."},{"key":"10.1016\/j.bcp.2026.117716_b0625","doi-asserted-by":"crossref","unstructured":"M. Pan, C. Yang, Z. Fu, Y. Yang, Y. Zhuo, H. Hou, J. Li, Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy, Adv Sci (Weinh) (2025) e01384.","DOI":"10.1002\/advs.202501384"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0630","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0635","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12916-022-02646-0","article-title":"Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study","volume":"20","author":"Xing","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.bcp.2026.117716_b0640","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47327","article-title":"FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy","volume":"8","author":"Diaz Osterman","year":"2019","journal-title":"Elife"},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.117716_b0645","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2024.42.16_suppl.4140","article-title":"Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: initial safety and efficacy of phase 1b\/2 study (RAMP 205)","volume":"42","author":"Lim","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0650","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s11033-025-10296-7","article-title":"Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors","volume":"52","author":"Aakriti","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2026.117716_b0655","doi-asserted-by":"crossref","unstructured":"L. Wu, J. Wang, L. Wang, W. Lu, K. Wang, A. Lin, N. Li, L. Li, N. Su, S. Xie, J. Jiang, A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer, Journal of Clinical Oncology 40(16_suppl) 5567\u20135567.","DOI":"10.1200\/JCO.2022.40.16_suppl.5567"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0660","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13046-021-01892-z","article-title":"Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma","volume":"40","author":"Le Large","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0665","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/pros.23476","article-title":"Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer","volume":"78","author":"Lin","year":"2018","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0670","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1158\/1535-7163.MCT-16-0282","article-title":"CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation","volume":"15","author":"Wang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0675","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1186\/s12885-022-09799-4","article-title":"Discovery of a novel ALK\/ROS1\/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0680","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.117716_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114318","article-title":"A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR\/FAK pathway inhibition","volume":"183","author":"Luo","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117716_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103408","article-title":"Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines","volume":"94","author":"Ai","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0695","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.radonc.2011.06.006","article-title":"Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures","volume":"99","author":"Eke","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0700","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/14756366.2021.2015344","article-title":"2-Arylquinolines as novel anticancer agents with dual EGFR\/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights","volume":"37","author":"Elbadawi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2026.117716_b0705","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.18632\/oncotarget.2397","article-title":"Overcoming EMT-associated resistance to anti-cancer drugs via Src\/FAK pathway inhibition","volume":"5","author":"Wilson","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150567","article-title":"Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor activity in Non-Small Cell Lung Cancer","volume":"11","author":"Howe","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0715","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bjc.2016.190","article-title":"Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways","volume":"115","author":"Zhang","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0720","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12964-023-01343-6","article-title":"FTO facilitates cancer metastasis by modifying the m(6)A level of FAP to induce integrin\/FAK signaling in non-small cell lung cancer","volume":"21","author":"Gao","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.bcp.2026.117716_b0725","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-17-0561","article-title":"Wnt\/\u03b2-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0730","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","article-title":"Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma","volume":"27","author":"Paradis","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2026.117716_b0735","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082280","article-title":"FAK Inhibitor-based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma","volume":"15","author":"Tarin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16_suppl","key":"10.1016\/j.bcp.2026.117716_b0740","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1200\/JCO.2024.42.16_suppl.8605","article-title":"Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: results from a phase Ib\/II study","volume":"42","author":"Song","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"565","key":"10.1016\/j.bcp.2026.117716_b0745","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2875","article-title":"Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer","volume":"12","author":"Schwill","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2026.117716_b0750","article-title":"Therapeutic suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117716_b0755","doi-asserted-by":"crossref","unstructured":"S. Coma, S. Chowdhury, M. Musteanu, A. Stewart, L. Pickard, M. Krebs, A. Minchom, U. Banerji, M. Barbacid, J. Pachter, P52.05 Dual RAF\/MEK Inhibitor VS-6766 for Treatment of KRAS Mutant NSCLC: Novel Combinations Targeting G12C or G12V Variants, Journal of Thoracic Oncology 16(10, Supplement) (2021) S1124.","DOI":"10.1016\/j.jtho.2021.08.549"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0760","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1078-0432.CCR-22-1609","article-title":"Development of Combination strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer","volume":"29","author":"Peng","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0765","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","article-title":"Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells","volume":"177","author":"Jarnicki","year":"2006","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0770","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","article-title":"Tumor-driven evolution of immunosuppressive networks during malignant progression","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0775","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-024-02974-4","article-title":"Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade","volume":"43","author":"Zhang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0780","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-023-00471-6","article-title":"Targeting focal adhesion kinase boosts immune response in KRAS\/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment","volume":"13","author":"Qiao","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117716_b0785","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1624128","article-title":"Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1(+) triple negative breast cancer cells","volume":"8","author":"Mohan","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2026.117716_b0790","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117716_b0800","article-title":"A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117716_b0805","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48092","article-title":"T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity","volume":"9","author":"Canel","year":"2020","journal-title":"Elife"},{"issue":"17","key":"10.1016\/j.bcp.2026.117716_b0810","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117065119","article-title":"Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis","volume":"119","author":"Ozmadenci","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.117716_b0795","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-017-0217-6","article-title":"FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer","volume":"5","author":"Symeonides","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0815","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1038\/s41598-019-41116-1","article-title":"Non-redundant functions of FAK and Pyk2 in intestinal epithelial repair","volume":"9","author":"Thomas","year":"2019","journal-title":"Sci. Rep."},{"issue":"237","key":"10.1016\/j.bcp.2026.117716_b0820","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0825","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41416-024-02727-2","article-title":"Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer","volume":"131","author":"Yoshimura","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.117716_b0830","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bpj.2014.11.3454","article-title":"Allosteric regulation of focal adhesion kinase by PIP2 and ATP","volume":"108","author":"Zhou","year":"2015","journal-title":"Biophys. J ."},{"issue":"12","key":"10.1016\/j.bcp.2026.117716_b0835","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126381","article-title":"The Development of FAK Inhibitors: a Five-Year Update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0840","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0845","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41589-021-00878-4","article-title":"Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity","volume":"17","author":"Imaide","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2026.117716_b0850","doi-asserted-by":"crossref","unstructured":"H. Taniguchi, S. Chakraborty, N. Takahashi, A. Banerjee, R. Caeser, Y.A. Zhan, S.E. Tischfield, A. Chow, E.M. Nguyen, Q. Villalonga \u00c1, P. Manoj, N.S. Shah, S. Rosario, O. Hayatt, R. Qu, E. de Stanchina, J. Chan, H. Mukae, A. Thomas, C.M. Rudin, T. Sen, ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer, Sci Adv 10(39) (2024) eado4618.","DOI":"10.1126\/sciadv.ado4618"},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0855","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-023-02674-5","article-title":"Convergence of YAP\/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression","volume":"42","author":"Ning","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2026.117716_b0860","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0865","doi-asserted-by":"crossref","DOI":"10.1063\/5.0244706","article-title":"Advances in nanotechnology for targeting cancer-associated fibroblasts: a review of multi-strategy drug delivery and preclinical insights","volume":"9","author":"Zhang","year":"2025","journal-title":"APL Bioeng."},{"key":"10.1016\/j.bcp.2026.117716_b0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115083","article-title":"Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer","volume":"202","author":"Mikhail","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0880","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-021-01998-4","article-title":"CD151 drives cancer progression depending on integrin alpha3beta1 through EGFR signaling in non-small cell lung cancer","volume":"40","author":"Zhu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0885","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41420-022-00905-w","article-title":"Long noncoding RNA LINC00518 contributes to proliferation and metastasis in lung adenocarcinoma via the miR-335-3p\/CTHRC1 Axis","volume":"8","author":"Shen","year":"2022","journal-title":"Cell Death Discov."},{"issue":"5","key":"10.1016\/j.bcp.2026.117716_b0890","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-04928-0","article-title":"Integrin \u03b13\/\u03b16 and \u03b1V are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117716_b0895","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-020-01009-7","article-title":"Abnormally activated OPN\/integrin alphaVbeta3\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer","volume":"13","author":"Fu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117716_b0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156135","article-title":"Diosmin reduces the stability of Snail and Cyclin D1 by targeting FAK to inhibit NSCLC progression","volume":"135","author":"Ma","year":"2024","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.bcp.2026.117716_b0905","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41401-025-01645-0","article-title":"Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK\/c-Jun pathways","volume":"47","author":"Wang","year":"2026","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522600047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:36:25Z","timestamp":1778646985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522600047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":180,"alternative-id":["S000629522600047X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117716","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117716"}}